BioSig Technologies, Inc. (BSGM) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by BioSig Technologies, Inc. on October 4, 2021. The registrant is a Delaware corporation with principal executive offices in Westport, Connecticut. The report discloses a material event under Item 7.01 (Regulation FD Disclosure) regarding the publication of a clinical study.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on a regulatory disclosure rather than financial performance data.
Material Changes
The primary material event is the publication of an article titled "Evaluation of a novel cardiac signal processing system for electrophysiology procedures: the PURE EP 2.0 study" in the Journal of Cardiovascular Electrophysiology. The article became available electronically with open access via the Wiley Online Library on September 23, 2021.
Guidance, Outlook, and Risks
The Company explicitly states it undertakes no obligation to update, supplement, or amend the materials attached to this report. The filing includes a standard disclaimer that the information furnished under Item 7.01 is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not intended to constitute a determination that the information is material or required by Regulation FD.
Investor Verification Checklist
- Verify the full text of the press release attached as Exhibit 99.1 for specific study results.
- Confirm the open access availability of the PURE EP 2.0 study article via the Wiley Online Library.
- Review subsequent filings for any updates or clarifications regarding the study's impact on the Company's product pipeline.
- Note that this 8-K does not contain updated financial statements or forward-looking guidance.